Ownership
Private
Employees
~50
Stage
Commercial
Modalities
Autologous cell therapyGene therapySmall molecule

Juniper Biologics General Information

Commercial-stage company focused on novel therapies in oncology, rare diseases, and gene therapy. Has acquired rights to multiple commercial products and is expanding distribution networks across Asia, Australia, Middle East and Africa.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Singapore,
Singapore

Drug Pipeline

chlormethine
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Juniper Biologics's pipeline data

Book a demo

Key Partnerships

Helsinn Healthcare, Caris Life Sciences, Ping An-Shionogi

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Juniper Biologics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Juniper Biologics's complete valuation and funding history, request access »

Juniper Biologics Investors

The Sylvan Group
Investor Type: Venture Capital
Holding: Minority